维京治疗公司(VKTX)在盘前大跌9.16%,引起了市场关注。
公司公布的2024年第四季度财报数据令人失望。财报显示,维京治疗公司当季每股亏损高达0.32美元,大幅逊于分析师普遍预期的每股亏损0.28美元。与去年同期相比,公司净亏损更是扩大了28%,达到3540万美元。
亏损超预期主要原因是公司研究与开发费用不断攀升,包括候选药物的制造成本、员工薪酬福利以及临床试验费用。虽然公司CEO表示在多个临床试验中取得进展,但业绩未如预期,加深了投资者对公司前景的担忧,引发资金抛售,推动股价暴跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.